Products for Research Use Only

DC-SX029

CAT: 0804-HY-160477-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-160477-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
DC-SX029 is a potent SNX10 protein-protein interaction (PPI) inhibitor with oral activity with an estimated KD constant of ~0.935 μM by surface plasmon resonance (SPR) . DC-SX029 blocks the SNX10-PIKfyve interaction, thereby decreased the TBK1/c-Rel signaling activation. DC-SX029 does not affect the protein level of SNX10. DC-SX029 has the potential for inflammatory bowel disease (IBD) research[1][2].
CAS Number
300713-88-6
UNSPSC
12352005
Target
IKK; NF-κB; PIKfyve
Type
Reference compound
Related Pathways
NF-κB; PI3K/Akt/mTOR
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/dc-sx029.html
Purity
98.07
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=C(S(=O)(NCC(C(F)(F)F)CCC(O)=O)=O)C=C1)OC
Molecular Formula
C14H17F3N2O6S
Molecular Weight
398.35
References & Citations
[1]Weilian Bao, et al. Targeting sorting nexin 10 improves mouse colitis via inhibiting PIKfyve-mediated TBK1/c-Rel signaling activation. Pharmacol Res. 2021 Jul:169:105679.|[2]Weilian Bao, et al. Inhibiting sorting nexin 10 promotes mucosal healing through SREBP2-mediated stemness restoration of intestinal stem cells. Sci Adv. 2023 Sep;9 (35) :eadh5016.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported